This podcast was organised and funded by Menarini Stemline. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Menarini Stemline or EMJ.
This episode focuses on the implications of ESR1 mutations in oestrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer.
The experts discuss the challenges faced in second-line therapy and the mechanisms of acquired resistance from ESR1 mutations, considering current practices and experiences of testing and identifying ESR1 mutations and how this impacts the management of ER+/HER2− metastatic breast cancer and treatment decision-making.
Host
Hannah Moir1
Speakers
Giuseppe Curigliano2
Virginia Kaklamani3
1. Moderator: Hannah Moir, EMJ, Principal Medical Writer, Moderator, and Educator, EMJ, London, UK Senior Fellow (Associate Professor in Health & Exercise Prescription), Faculty of Health, Science, Social Care and Education, Kingston University, London, UK
2. Expert: Giuseppe Curigliano, Director of Early Drug Development and co-chair for Experimental Therapeutics Programme at the European Institute of Oncology, Milan, Italy, Professor of Medical Oncology, Department of Oncology and Hemato-Oncology, University of Milan, President-Elect of the European Society for Medical Oncology (ESMO).
3. Expert: Virginia Kaklamani, Professor of Medicine in the Division of Hematology-Medical Oncology at The University of Texas Health Science Center, San Antonio, USA. Leader of the Breast Cancer Programme in the Mays Cancer Center, and Co-Director of the Cancer Genetics Program, at the UT Health San Antonio MD Anderson Cancer Center, USA. Co-Director of the San Antonio Breast Cancer Symposium (SABCS) international research symposium, USA.
